We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI-Based Technology Identifies Genetic Causes of Serious Diseases

By LabMedica International staff writers
Posted on 28 Oct 2021
Print article
Image: Schematic Diagram of Fabric GEM workflow that provides fast, accurate results for any clinical NGS test (Photo courtesy of Fabric Genomics)
Image: Schematic Diagram of Fabric GEM workflow that provides fast, accurate results for any clinical NGS test (Photo courtesy of Fabric Genomics)
Clinical interpretation of genetic variants in the context of the patient’s phenotype is becoming the largest component of cost and time expenditure for genome-based diagnosis of rare genetic diseases.

The genome interpretation process consists of iterative variant filtering, coupled with evidence-based review of candidate disease-causing variants. Artificial intelligence (AI) holds promise to greatly simplify and speed genome interpretation by integrating predictive methods with the growing knowledge of genetic disease.

An international team of Genomic Medicine Scientists collaborating with those at the University of Utah School of Medicine (Salt Lake City, UT, USA) assessed the diagnostic performance of Fabric GEM (Fabric Genomics Inc., Oakland, CA, USA) a new, AI-based, clinical decision support tool for expediting genome interpretation. They benchmarked GEM in a retrospective cohort of 119 probands, mostly NICU infants, diagnosed with rare genetic diseases, who received whole-genome or whole-exome sequencing (WGS, WES). They replicated their analyses in a separate cohort of 60 cases collected from five academic medical centers. For comparison, they also analyzed these cases with current state-of-the-art variant prioritization tools.

The investigators reported that GEM ranked over 90% of the causal genes among the top or second candidate and prioritized for review a median of three candidate genes per case, using either manually curated or clinical natural language processing (CNLP)-derived phenotype descriptions. Ranking of trios and duos was unchanged when analyzed as singletons. In 17 of 20 cases with diagnostic structural variants (SVs), GEM identified the causal SVs as the top candidate and in 19/20 within the top five, irrespective of whether SV calls were provided or inferred ab initio by GEM using its own internal SV detection algorithm. GEM showed similar performance in absence of parental genotypes. Analysis of 14 previously unsolved cases resulted in a novel finding for one case, candidates ultimately not advanced upon manual review for three cases, and no new findings for 10 cases.

Mark Yandell, PhD, a professor of human genetics and co-corresponding author on the study, said, “Critically ill children rapidly accumulate many pages of clinical notes. The need for physicians to manually review and summarize note contents as part of the diagnostic process is a massive time sink. The ability of Clinithink’s tool to automatically convert the contents of these notes in seconds for consumption by GEM is critical for speed and scalability.” Clinithink (Alpharetta, GA, USA) is a technology company built around CLiX, the world’s first Healthcare AI capable of truly understanding unstructured medical notes.

The authors concluded that GEM enabled diagnostic interpretation inclusive of all variant types through automated nomination of a very short list of candidate genes and disorders for final review and reporting. In combination with deep phenotyping by CNLP, GEM enables substantial automation of genetic disease diagnosis, potentially decreasing cost and expediting case review. The study was published on October 14, 2021 in the journal Genomic Medicine.

Related Links:
University of Utah
Fabric Genomics Inc
Clinithink


Gold Member
Troponin T QC
Troponin T Quality Control
Unit-Dose Packaging solution
HLX
New
Monkeypox Test
Monkeypox Virus Rapid Antibody Test
New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.